Genetic determinants of dose and clinical outcomes in patients receiving oral anticoagulants.

C Michael Stein, Ute I Schwarz

Journal: Clinical pharmacology and therapeutics 2006;80(1):7-12

PMID: 16815312

Full Text on Ovid Technologies, Inc. View on PubMed

Abstract

Address: Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA. [email protected]

DOI: 10.1016/j.clpt.2006.04.008

Link outs

Free resources

Medical:

https://medlineplus.gov/bloodthinners.html

Other Literature Sources:

https://www.lens.org/lens/search/patent/list?q=ref...

Subscription / membership required

Full Text Sources:

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linko...
https://doi.org/10.1016/j.clpt.2006.04.008

MeSH Terms: Acenocoumarol, Administration, Oral, Anticoagulants, Aryl Hydrocarbon Hydroxylases, Cytochrome P-450 CYP2C9, Genotype, Humans, Mixed Function Oxygenases, Vitamin K Epoxide Reductases, Warfarin